Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer [0.03%]
空间转录组揭示HR阳性/HER2阴性早期乳腺癌内分泌治疗反应相关生物标志物
Yujing Tan,Jiani Wang,Zhe Chen et al.
Yujing Tan et al.
Objective: Endocrine resistance occurs in nearly all patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), which can develop local and distant rec...
Tumor-metabolism integrated therapy: A new paradigm for fertility-sparing treatment in endometrial cancer [0.03%]
肿瘤代谢整合治疗：子宫内膜癌保留生育功能新策略
Tao Xing,Jianliu Wang
Tao Xing
Early prediction of synergistic cardiotoxicity induced by PD-1 inhibitors and doxorubicin using cardiac 18F-FDG PET/MRI [0.03%]
PD-1抑制剂联合多柔比星引起的心脏毒性早期预测的18F-FDG PET/MRI研究
Yuqi Cai,Tingting Yuan,Xiaoxia Xu et al.
Yuqi Cai et al.
Objective: Early detection of synergistic cardiotoxicity induced by sequential anthracycline and programmed cell death protein 1 (PD-1) inhibitor therapy remains challenging because conventional assessments identify late-...
Is sentinel node navigation surgery feasible after non-curative endoscopic resection in patients with early gastric cancer? [0.03%]
内镜下非治愈性切除的早期胃癌患者可行哨点淋巴结导航手术吗？
Bang Wool Eom,Woo Jun Ahn,Hong Man Yoon et al.
Bang Wool Eom et al.
Development and validation of a neutrophil percentage to albumin ratio-based nomogram for predicting survival in patients with locally advanced gastric cancer [0.03%]
基于中性粒细胞比例血清白蛋白比值的列线图在预测局部晚期胃癌患者预后中的开发和验证
Shunyu Deng,Maoxing Liu,Fei Tan et al.
Shunyu Deng et al.
Objective: This study aimed to clarify the predictive value of the neutrophil percentage to albumin ratio (NPAR) for postoperative survival in patients with locally advanced gastric cancer (LAGC) and to develop a prognost...
Lijuan Hu,Yi Xia,Xiaodong Mo et al.
Lijuan Hu et al.
Acute leukemia remains a life-threatening hematologic malignancy with historically poor outcomes in relapsed/refractory and elderly patients. Over the past decade, measurable residual disease (MRD) has evolved from a prognostic indicator to...
Managing evolution of metastatic prostate cancer: From hormone-sensitive to castration-resistant disease [0.03%]
前列腺癌的演化管理：从激素敏感型到去势抵抗型疾病
Shengpan Wu,Xu Zhang
Shengpan Wu
Turmoil and breakthroughs: Highlights and growing pains in breast cancer therapy 2025 - 2026 [0.03%]
波澜与突破：2025-2026年乳腺癌治疗的亮点和成长的烦恼
Mingxia Jiang,Binghe Xu
Mingxia Jiang